FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2537151572> ?p ?o ?g. }

• W2537151572 abstract "Abstract Abstract 1688 Introduction: Allogeneic stem cell transplantation (allo-SCT) remains an important option for patients with chronic myeloid leukemia (CML) who failed tyrosine kinase inhibitors (TKI). Data on CML patients after allo-SCT in the TKI era are rare. Meanwhile, patients are more often submitted to allo-SCT beyond first chronic phase (CP) which leads to poorer outcome (Sauβele et al. Blood 2010, BMT 2011). Therefore the aim of this study was to evaluate the outcome of CML patients after allo-SCT within the EUTOS (European Treatment and Outcome Study) for CML registry. Methods: The “In-study” registry section collects data of patients recruited to trials of national study groups (France, Germany, Italy, Spain, The Netherlands, Nordic European Countries, UK). The “Out-Study” registry section collects data of patients within national registries (Czech Republic, Poland, Romania, Russia, Spain, UK). Inclusion criteria were Philadelphia chromosome or BCR-ABL positive CML diagnosed between 2002–2006, treatment with imatinib within 6 months after diagnosis and age ≥ 18 years. Results: “In-study” registry section: 2060 patients were registered. 556 patients from France were excluded since no data on allo-SCT were available. 1504 patients were evaluable. Allo-SCT was reported in 91 patients (6%). Of these, 52 were from Germany, 16 from Italy, 4 from the Nordic countries (Sweden, Norway, Finland and Island) and 19 from the Netherlands. The transplantation rate varied between countries: Germany 52 out of 699 (7%), Italy 16 out of 546 (3%), Nordic countries 4 out of 140 (3%) and The Netherlands 19 out of 119 (16%). Characteristics of the 91 patients were: 65% were men (compared to 59% in the total cohort), median age was 42 years (range 18–65; compared to 52 years in the total cohort), median therapy duration before allo-SCT was 16.1 months (range 3.5–55.9 months), median follow-up after transplantation was 51.5 months (range 10.9–71.9). 68 patients were transplanted in chronic phase, 23 after progression, i.e. beyond first CP. Two year OS was 84.1% for chronic phase patients and 30.4% for patients in advanced phases. “Out-study” section: 1536 patients were registered and evaluable. Allo-SCT was reported in 60 patients (4%), 1 from Romania (1 of 13, 8%), 20 from Czech Republic (20 of 333, 6%), 20 from Poland (20 of 283, 7%), 3 from Spain (3 of 184, 2%), 5 from Russia (5 of 606, 1%) and 11 from UK (11 of 117, 9%). Patients' characteristics were: 59% were male (compared to 52% in the total cohort), median age was 34 years (range 18–60 years, total cohort 48 years), median time to transplantation 12 months (range 3 to 64 months). Outcome data in this section will be updated at the ASH meeting. Combining the “in-study” and “out-study” registries, overall 151 out of 3040 evaluable patients (5%) have been submitted to allo-SCT. Conclusion: Transplantation rates between countries participating in the EUTOS for CML registry vary substantially. Survival data from the “in-study” registry show that allo-SCT remains an attractive and important rescue therapy for CML patients. This survey deals with patient diagnosed between 2002–2006; an epidemiological EUTOS registry, open to all patients diagnosed since mid 2009 will investigate the rate of allo-SCT after the implementation of second generation TKI in CML treatment Europe-wide. Disclosures: Saussele: EUTOS for CML: Research Funding, is a cooperation as per contract between ELN and Novartis. Piccolo:Novartis: Employment." @default.
• W2537151572 created "2016-10-28" @default.
• W2537151572 creator A5003294629 @default.
• W2537151572 creator A5009003698 @default.
• W2537151572 creator A5013024565 @default.
• W2537151572 creator A5016147985 @default.
• W2537151572 creator A5018111458 @default.
• W2537151572 creator A5018592613 @default.
• W2537151572 creator A5023052390 @default.
• W2537151572 creator A5024769189 @default.
• W2537151572 creator A5035321251 @default.
• W2537151572 creator A5035964802 @default.
• W2537151572 creator A5038000746 @default.
• W2537151572 creator A5044224344 @default.
• W2537151572 creator A5054654885 @default.
• W2537151572 creator A5058931835 @default.
• W2537151572 creator A5059723473 @default.
• W2537151572 creator A5060416371 @default.
• W2537151572 creator A5062230211 @default.
• W2537151572 creator A5066994665 @default.
• W2537151572 creator A5074486986 @default.
• W2537151572 creator A5075849003 @default.
• W2537151572 creator A5079181777 @default.
• W2537151572 creator A5079423630 @default.
• W2537151572 creator A5086462994 @default.
• W2537151572 creator A5089471811 @default.
• W2537151572 date "2011-11-18" @default.
• W2537151572 modified "2023-10-17" @default.
• W2537151572 title "Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry" @default.
• W2537151572 doi "https://doi.org/10.1182/blood.v118.21.1688.1688" @default.
• W2537151572 hasPublicationYear "2011" @default.
• W2537151572 type Work @default.
• W2537151572 sameAs 2537151572 @default.
• W2537151572 citedByCount "0" @default.
• W2537151572 crossrefType "journal-article" @default.
• W2537151572 hasAuthorship W2537151572A5003294629 @default.
• W2537151572 hasAuthorship W2537151572A5009003698 @default.
• W2537151572 hasAuthorship W2537151572A5013024565 @default.
• W2537151572 hasAuthorship W2537151572A5016147985 @default.
• W2537151572 hasAuthorship W2537151572A5018111458 @default.
• W2537151572 hasAuthorship W2537151572A5018592613 @default.
• W2537151572 hasAuthorship W2537151572A5023052390 @default.
• W2537151572 hasAuthorship W2537151572A5024769189 @default.
• W2537151572 hasAuthorship W2537151572A5035321251 @default.
• W2537151572 hasAuthorship W2537151572A5035964802 @default.
• W2537151572 hasAuthorship W2537151572A5038000746 @default.
• W2537151572 hasAuthorship W2537151572A5044224344 @default.
• W2537151572 hasAuthorship W2537151572A5054654885 @default.
• W2537151572 hasAuthorship W2537151572A5058931835 @default.
• W2537151572 hasAuthorship W2537151572A5059723473 @default.
• W2537151572 hasAuthorship W2537151572A5060416371 @default.
• W2537151572 hasAuthorship W2537151572A5062230211 @default.
• W2537151572 hasAuthorship W2537151572A5066994665 @default.
• W2537151572 hasAuthorship W2537151572A5074486986 @default.
• W2537151572 hasAuthorship W2537151572A5075849003 @default.
• W2537151572 hasAuthorship W2537151572A5079181777 @default.
• W2537151572 hasAuthorship W2537151572A5079423630 @default.
• W2537151572 hasAuthorship W2537151572A5086462994 @default.
• W2537151572 hasAuthorship W2537151572A5089471811 @default.
• W2537151572 hasConcept C126322002 @default.
• W2537151572 hasConcept C187212893 @default.
• W2537151572 hasConcept C2777583451 @default.
• W2537151572 hasConcept C2778729363 @default.
• W2537151572 hasConcept C2911091166 @default.
• W2537151572 hasConcept C3019892230 @default.
• W2537151572 hasConcept C71924100 @default.
• W2537151572 hasConceptScore W2537151572C126322002 @default.
• W2537151572 hasConceptScore W2537151572C187212893 @default.
• W2537151572 hasConceptScore W2537151572C2777583451 @default.
• W2537151572 hasConceptScore W2537151572C2778729363 @default.
• W2537151572 hasConceptScore W2537151572C2911091166 @default.
• W2537151572 hasConceptScore W2537151572C3019892230 @default.
• W2537151572 hasConceptScore W2537151572C71924100 @default.
• W2537151572 hasLocation W25371515721 @default.
• W2537151572 hasOpenAccess W2537151572 @default.
• W2537151572 hasPrimaryLocation W25371515721 @default.
• W2537151572 isParatext "false" @default.
• W2537151572 isRetracted "false" @default.
• W2537151572 magId "2537151572" @default.
• W2537151572 workType "article" @default.